News Briefing channel feed

MannKind el­e­vates Cas­tan­ga to CEO; 23andMe re­cruits 5,000 women for study in 9 days

8 years ago

Venn and Uni­ver­si­ty of Utah part­ner on im­muno-on­col­o­gy mol­e­cule; Bio­gen los­ing an­oth­er ex­ec

9 years ago

New car­dio tar­get ANGPTL3 with promis­ing new stud­ies; Liv­er­pool says Redx is delin­quent; Aslan's $33M Taipei IPO

9 years ago

Im­muno­Gen gets $25M up­front for ADC ther­a­py; mi­Ra­gen adds Eu­ro­pean or­phan drug des­ig­na­tion; Pierre Fab­re buys some pre­clin­i­cal im­munother­a­pies

9 years ago

As­traZeneca cheers a suc­cess for PhI­II ben­ral­izum­ab study; TP rais­es $45M for can­cer drug

9 years ago

Abl­ynx grabs a €15M mile­stones pay­ment from Mer­ck KGaA; Eye­Gate surges on Valeant pay­out

9 years ago

Astel­las, Pfiz­er scrap a PhI­II breast can­cer study us­ing Xtan­di; New $30M fund will back Is­raeli biotech star­tups

9 years ago

Is­rael's Te­va puts for­eign­er in line for CEO's job; Ver­tex wins ex­pand­ed la­bel for Ka­ly­de­co

9 years ago

Deci­bel chief Holtz­man cham­pi­ons Fen­way as the new ‘hood in biotech; Aduro adds 2nd Keytru­da com­bo for can­cer

9 years ago

Or­biMed, J&J back $24M A round for mi­cro­bio­me start­up; Sang­amo, Pfiz­er win FDA fast track

9 years ago

Igny­ta jumps on an FDA ‘break­through’ nod for en­trec­tinib; Ther­mo Fish­er buy­ing Patheon in $7.2B deal

9 years ago

Capri­cor shares blast­ed as PhII heart study fails; Sanofi to de­stroy un­used fa­cil­i­ty in France

9 years ago

Astel­las dumps a PhI­II lung can­cer drug; GSK gets one suc­cess, one fail­ure in a pair of piv­otal Crohn’s tri­als

9 years ago

As M&A buzz heats up, Parex­el plans 1,200 lay­offs; Grü­nen­thal is hir­ing for its new Boston/Cam­bridge cen­ter

9 years ago

Scott Got­tlieb clears an­oth­er hur­dle in last stretch ahead of the FDA; Sanofi inks €250M bis­pe­cif­ic dis­cov­ery deal in meta­bol­ics

9 years ago

Abrax­is vet Neil De­sai gets Cel­gene back­ing for $23M A round; Two more biotechs set IPO terms

9 years ago

Gates Foun­da­tion fu­els Achao­gen’s an­ti­body plat­form with $20.5M com­mit­ment; Igny­ta rais­es $77M

9 years ago

For­mer GSK can­cer R&D chief Pao­let­ti takes the reins at Gam­maDelta; Blue­print inks big Cam­bridge lease

9 years ago

Am­gen backs WuXi NextCODE’s $75M B round; Im­Check bags €20 ven­ture round for I-O work

9 years ago

Cure­Vac names a US sub­sidiary CEO to ad­vance mR­NA work; Sune­sis shares slide af­ter reg­u­la­tors nix drug app

9 years ago

Robert Plenge tapped to run im­munol­o­gy R&D at Cel­gene; Tesaro files LAG-3 IND

9 years ago

Bris­tol-My­ers passed on its $475M deal to op­tion F-star drug; Zymeworks IPO rais­es $59M

9 years ago

Tesaro gets its PD-1 reg­is­tra­tion study start­ed, hunt­ing ac­cel­er­at­ed OK; Ul­tragenyx hus­tles in­to PhI­II

9 years ago

An­a­lysts of­fer a luke­warm en­dorse­ment to Am­gen for PhI­II mi­graine da­ta; Ar­sa­nis rais­es $45.5M Se­ries D; Co­v­ance faces re­struc­tur­ing

9 years ago
First page Previous page 69707172737475 Next page Last page
A service from the Financial Times